Immunological evaluation of OMP-F of native Iranian Pseudomonas aeruginosa as a protective vaccine

Journal of Infection in Developing Countries

Volumn 6, Issue 10, 2012, Pages 721-726

  Ahmadi, Hojat ^a   Tabaraie, Bahman ^a   Maleknia, Shayan ^a   Pormirzagholi, Farahnaz ^a   Nejati, Mehdi ^a   Hedayati, Mohammad Hosein ^a  

^a PASTEUR INSTITUTE OF IRAN   (Iran)

Author keywords

OMP F; Protective immunogen; Pseudomonas aeruginosa; Purification

Indexed keywords

EID: 84868008538     PISSN: 19722680     EISSN: None     Source Type: Journal    
DOI: 10.3855/jidc.2220     Document Type: Article

References (25)

1. Peluso L, de Luca C, Bozza S, Leonardi A, Giovannini G, Lavorgna A, De Rosa G, Mascolo M, De Luna L. O, Catania M. R, Romani L, Rossano F (2010) Protection against Pseudomonas aeruginosa lung infection in mice by recombinant OprF-pulsed dendritic cell immunization. BMC Microbiology 10: 1-11.
2. Gaynes R and Edwards JR (2005) Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis 41: 848-854.
3. Pellizzer G, Mantoan P, Timillero L, Allegranzi B, Fedeli U, Schievano E, Benedetti P, Saia M, Sax H, Spolaore P (2008) Prevalence and risk factors for nosocomial infections in hospitals of the Veneto region, north-eastern Italy. Infection 36: 112-119.
4. Chastre J and Fagon JY (2002) Ventilator-associated pneumonia. Am J Respir Crit Care Med 165: 867-903.
5. Wu M, Guina T, Brittnacher M, Nguyen H, Eng J, Miller SI (2005) The Pseudomonas aeruginosa proteome during anaerobic growth. J Bacteriology 23: 8185-8190.
6. Mesaros N, Nordmann P, Plesiat P, Roussel-Delvallez M, Van Eldere J, Glupczynski Y, Van Laethem Y, Jacobs F, Lebecque P, Malfroot A, Tulkens PM, Van Bambeke F (2007) Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium. Clin Microbiol Infect 13: 560-578.
7. Hideo Kusama (1978) Serological classification of Pseudomonas aeruginosa by a slide agglutination test. JCM 2: 181-188.
8. Ahmadi H MalekniaSh, Tabaraie B, Norouzian D, Poormirza-gholi F, Nejati M, Hedayati MH, Beik Mohammadi MR, Behnoodi A, Izadpanahi M (2010) Antigenic serotyping and cross-reactivity between different Pseudomonas aeruginosa isolates prevalent in Iran. Iranian J Microbiology 2: 85-88.
9. Cripps AW, Peek K, Dunkley M, Vento K, Marjason JK, McIntyre ME, Sizer P, Croft D, Sedlak-Weinstein L (2006) Safety and immunogenicity of an oral inactivated whole-cell Pseudomonas aeruginosa vaccine administered to healthy human subjects. Infect Immun 74: 968-974.
10. Gilleland HE Jr, Parker MG, Matthews JM, Berg RD (1984) Use of a purified outer membrane protein F (porin) preparation of Pseudomonas aeruginosa as a protective vaccine in mice. Infect Immun 44: 49-54.
11. Greer JM and Gilleland HE (1987) Outer membrane protein F (porin) preparation of Pseudomonas aeruginosaas a protective vaccine against heterologous immunotype strains in a burned mouse model. J Infect Dis 155: 1282.
12. Gilleland HE Jr, Gilleland LB, Matthews-Greer JM (1988) Outer membrane protein F preparation of Pseudomonas aeruginosa as a vaccine against chronic pulmonary infection with heterologous immunotype strains in a rat model. Infect Immun 56: 1017-1022.
13. von Specht BU, Lucking HC, Blum B, Schmitt A, Hungerer KD, Domdey H (1996) Safety and immunogenicity of a Pseudomonas aeruginosa outer membrane protein I vaccine in human volunteers. Vaccine 14: 1111-1117.
14. Lee NG, Jung SB, Ahn BY, Kim YH, Kim JJ, Kim DK, Kim IS, Yoon SM, Nam SW, Kim HS, Park WJ (2000) Immunization of burn-patients with a Pseudomonas aeruginosa outer membrane protein vaccine elicits antibodies with protective efficacy. Vaccine 18: 1952-1961.
15. Battershill JL, Speert DP, Hancock RE (1987) Use of monoclonal antibodies to protein F of Pseudomonas aeruginosa as opsonins for phagocytosis by macrophages. Infect Immun 55: 2531-2533.
16. Lee NG, Ahn BY, Jung SB, Kim YG, Lee Y, Kim HS, Park WJ (1999) Human anti-Pseudomonas aeruginosa outer membrane proteins IgG cross-protective against infection with heterologous immunotype strains of P. aeruginosa. FEMS Immunol Med Microbiol 25: 339-347.
17. Baumann U, Mansouri E, von Specht BU (2004) Recombinant OprF-OprI as a vaccine against Pseudomonas aeruginosa infections. Vaccine 22: 840-847.
18. Hughes EE and Gilleland HE Jr (1995) Ability of synthetic peptides representing epitopes of outer membrane protein F of Pseudomonas aeruginosa to afford protection against P. aeruginosa infection in a murine acute pneumonia model. Vaccine 13: 1750-1753.
19. Classen I, Meylis J, Loy PV, Peeters C, Brons H, Robert J, Borsboom D, van der Ark A, van Straaten I, Roholl P, Kuipers B, Poolman J (1996) Production, characterization and control of Neisseria meningitides hexavalent class 1 outer membrane protein containing vesicles vaccine. Vaccine 14: 1001-1008.
20. Miller JJ, Spilsbury JF, Jones RJ, Roe EA, Lowbury EJL (1977) A new polyvalent Pseudomonas vaccine. J Med Microbiology 10: 19-27.
21. Pier GB, Sidberry HF, Sadoff JC (1978) Protective immunity induced in mice by immunization with high-molecular-weight polysaccharide from Pseudomonas aeruginosa. Infect Immun 22: 919-925.
22. Hancock RE and Nikaido H (1978) Outer membranes of gram-negative bacteria. XIX. Isolation from Pseudomonas aeruginosa PAO1 and use in reconstitution and definition of the permeability barrier. J Bacteriol 136: 381-390.
23. Tabaraie B, Sharma BK, Sharma P, Ganguly NK (1992) Evaluation of immunoprophilactic activities of purified porins of Salmonella typhi 0-901 and Salmonella typhimurium Ra-c. Vaccine 4: 278.
24. Robert EW and Carey AM (1979) Outer membrane of Pseudomonas aeruginosa: Heat-and 2-Mercaptoethano (-Modifiable proteins). Journal of Bacteriology 140: 902-910.
25. von Specht BU, Lücking HC, Blum B, Schmitt A, Hungerer KD, Domdey H (1996) Safety and immunogenicity of a Pseudomonas aeruginosa outer membrane protein I vaccine in human volunteers. Vaccine 14: 1111-1117.